The Innovation Management Board will ensure that:
- the Intellectual Property provisions of the FAIR-PARK II Consortium Agreement are adhered to throughout the project,
- appropriate forms of Intellectual Property protection are sought,
- the consortium members receive support in drawing up project exploitation plans.
The Innovation Management Board will be composed of technology transfer officers from each partner organisation of FAIR-PARK II:
Participant N° | Participant organisation name | Short Name | Name |
---|---|---|---|
1 |
Centre Hospitalier Regional et Universitaire de Lille |
CHRUL |
Marie-Anne ALLAIN |
2a |
Institut National de la Santé et de la Recherche Médicale |
INSERM |
Jean-Christophe Corvol |
2b |
Institut National de la Santé et de la Recherche Médicale |
INSERM |
Olivier Rascol |
3 |
European Clinical Research Infrastructure Network |
ECRIN |
Jacques Demotes |
4 (Chairman) |
Inserm Transfert |
IT |
Denise Hirsch |
5 |
Apo-Pharma Inc. |
APOPHARMA |
Michael Spino |
6 |
Instituto de Medicina Molecular |
IMM |
Joaquim Ferreira |
7 |
Fundació privada Clínic per a la Recerca Biomèdica |
FCRB |
Eduardo Tolosa |
8 |
University of Newcastle upon Tyne |
UNEW |
David Burn |
9 |
Eberhard Karls Universitaet Tuebingen |
EKUT |
Holm Graessner |
10 |
Medizinische Universitat Innsbruck |
MUI |
Werner Poewe |
11 |
Univerzita Karlova v Praze |
CUP |
Evžen Růžička |
12 |
Stichting Katholieke Universiteit |
RUNMC |
Martijn Bakker |
13 |
Philipps Universitat Marburg |
PUM |
Dr. Sandra Basenau |
14 |
Université Pierre et Marie Curie |
UPMC |
Marie-Odile Habert |
15 |
Universitaet Ulm |
UULM |
Markus Otto |
16 | Christian-Albrechts-Universitaet | CAU | Daniela Berg |